Skip to Main Content

search input Search input auto suggest

Search

Menu

Innovations Journals Home
About The Journal
Browse Journal
- Ahead of Print
- All Issues
Submit an Article
Become a Reviewer
Search
Contact Us
subscribe

Issues

Select Year

Select Issue

Volume 3, Issue 1

1 February 2020

ISSN 2666-2345

eISSN 2590-017X

In this Issue

LETTER TO THE EDITOR
REVIEW ARTICLES
Case Reports
Guideline and Consensus
Industry News

LETTER TO THE EDITOR

Cancer Immunotherapy for Immunocompromised Patients: An Often Ignored, yet Vital Puzzle

Jyoti Bajpai

Extract

REVIEW ARTICLES

Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms

Mihailo Miljanic; Anna Capasso; Todd A. Triplett; S. Gail Eckhardt; Kyaw L. Aung

Abstract

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

Martin V. Nguyen; Lydia Loof; Gerald S. Falchook

Abstract

Case Reports

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review

Katherine Emilie Rhoades Smith; Emilie Elise Hitron; Greta A Russler; Deborah A Baumgarten; Mehmet Asim Bilen

Abstract

Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids

Maroun Sadek; Angela Loizidou; Annie Drowart; Sigi Van den Wijngaert; Maria Gomez-Galdon; Sandrine Aspeslagh

Abstract

A Case Report of a Cutaneous Mucinous Reaction Associated with Erlotinib Therapy Used in the Treatment of Metastatic Tonsillar Sinus Squamous Cell Carcinoma

Benjamin D Freemyer; Torres-Carlos A Cabala; Anisha B Patel

Abstract

Guideline and Consensus

Highlights on the Management of Oligometastatic Disease

Salem M. Alshehri; Khaled Alkattan; Ahmed Abdelwarith; Hussain Alhussain; Shaker Shaker; Majed Alghamdi; Hossam Alassaf; Ali Albargawi; Manal Al Naimi; Ameen Alomair; Saif Althaqfi; Adnan Alhebshi; Majid Alothman; AbdulRahman Jazieh

Abstract

Industry News

Introducing the 3^rd Annual PARP and DNA Damage Response Inhibitors Summit

Extract

IO360° Speaker Interview: Q and A with Dr. Crystal Mackall

Extract

Finding T-Cure: A CEO's vision for the future of adoptive cell immunotherapy

Extract

Cover Image

Cover Image

Get Email Alerts

Latest Issue Alert

Latest
Most Read
Most Cited

Repurposing Interleukin-6 Inhibitors to Combat COVID-19

Shumei Kato, Razelle Kurzrock

When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma

Vanina E. Wainsztein, Tom W. Chen

Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results

Ella Achenbach, David Lai, Shiraj Sen

Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations

Elias A. Chandran, Ian Kennedy

RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer

Sang T. Kim, William A. Murphy, Jr, Ana Aparicio, Sumit K. Subudhi

eISSN 2590-017X
ISSN 2666-2345

Privacy Policy
Get Adobe Acrobat Reader
Support

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept